ReviewToxins2025
Species Differences in the Biotransformation of Aflatoxin B1: Primary Determinants of Relative Carcinogenic Potency in Different Animal Species.
Review in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Next-generation probiotics and microbiome-based therapeutics highlighting Akkermansia muciniphila and Amuc_1100.World journal of microbiology & biotechnology · 2026Review
- Epidemiological risk factors and inferred p53 pathway dysregulation in Esophageal squamous cell carcinoma in the Somali population.Discover oncology · 2026Review
- Review
- Aflatoxins and Fumonisins: Assessment Methods, Biomarkers of Exposure, Modified Forms, Co-Exposure, and Impact on Human Health.Molecules (Basel, Switzerland) · 2026Review
- Molecularly imprinted polymer-coated metal-organic cages as ambient ionization probes for rapid detection of aflatoxins in peanut and corn.Mikrochimica acta · 2026Article
- Editorial: Introduction to theToxins · 2026Article
- Occurrence of mycotoxins in fish feed and its consequences for aquaculture with special regard to the role of insect products.Mycotoxin research · 2026Review
- Discovery of flavonoids as potent inhibitors of CYP1A to alleviate cellular inflammation and oxidative stress induced by benzo[a]pyrene-induced high CYP1A expression.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Review
- Greener Solutions in Aflatoxin Management: Transitioning from Conventional Binders to Green Nanotechnology.Nanomaterials (Basel, Switzerland) · 2025Review
- Protective effect of capsaicin on AKT1 and MAPK1 expression in the liver of mice (Open veterinary journal · 2025Article
- Impact of Aflatoxins on the Digestive, Immune, and Nervous Systems: The Role of Microbiota and Probiotics in Toxicity Protection.International journal of molecular sciences · 2025Review
- Aflatoxin Exposure in Immunocompromised Patients: Current State and Future Perspectives.Toxins · 2025Review
- Aflatoxin MToxins · 2025Article
- Multiple Mycotoxin Contamination in Livestock Feed: Implications for Animal Health, Productivity, and Food Safety.Toxins · 2025Review
- Environmental risk factors for liver cancer.Hepatology (Baltimore, Md.) · 2025Article
- Biomarker-based evaluation of aflatoxin B1 exposure in cattle.Veterinary world · 2025Article
- Review
- Structurally Similar Mycotoxins Aflatoxin BToxins · 2025Article
- Fifty Years of Aflatoxin Research in Qidong, China: A Celebration of Team Science to Improve Public Health.Toxins · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been known since the early days of the discovery of aflatoxin B1 (AFB1) that there were large species differences in susceptibility to AFB1. It was also evident early on that AFB1 itself was not toxic but required bioactivation to a reactive form. Over the past 60 years there have been thousands of studies to delineate the role of ~10 specific biotransformation pathways of AFB1, both phase I (oxidation, reduction) and phase II (hydrolysis, conjugation, secondary oxidations, and reductions of phase I metabolites). This review provides a historical context and substantive analysis of each of these pathways as contributors to species differences in AFB1 hepatoxicity and carcinogenicity. Since the discovery of AFB1 as the toxic contaminant in groundnut meal that led to Turkey X diseases in 1960, there have been over 15,000 publications related to aflatoxins, of which nearly 8000 have addressed the significance of biotransformation (metabolism, in the older literature) of AFB1. While it is impossible to give justice to all of these studies, this review provides a historical perspective on the major discoveries related to species differences in the biotransformation of AFB1 and sets the stage for discussion of other papers in this Special Issue of the important role that AFB1 metabolites have played as biomarkers of exposure and effect in thousands of human studies on the toxic effects of aflatoxins. Dr. John Groopman has played a leading role in every step of the way-from initial laboratory studies on specific AFB1 metabolites to the application of molecular biomarkers in epidemiological studies associating dietary AFB1 exposure with liver cancer, and the design and conduct of chemoprevention clinical trials to reduce cancer risk from unavoidable aflatoxin exposures by alteration of specific AFB1 biotransformation pathways. This article is written in honor of Dr. Groopman's many contributions in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.